Filings under TTRX by Tetragenex Pharmaceuticals, Inc. (CIK 0001362659) from Jul 26, 2007 to Nov 29, 2007 belong to a different issuer and are not shown.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Gengos Andrew | Director | Grant(A) | 95K | — | $0 |
| Jun 4, 2026 | Golden Arthur F | Director | Grant(A) | 90K | — | $0 |
| Jun 4, 2026 | Dewhurst Martin William | Director | Grant(A) | 72K | — | $0 |
| Jun 4, 2026 | Kester Kent Edward | Director | Grant(A) | 83K | — | $0 |
| May 28, 2026 | Burnam Bradley Evan | Chief Executive Officer, Director, 10% Owner | Gift(G) | 300K | — | $0 |
| May 28, 2026 | Burnam Bradley Evan | Chief Executive Officer, Director, 10% Owner | Gift(G) | 300K | — | $0 |
| May 28, 2026 | Burnam Bradley Evan | Chief Executive Officer, Director, 10% Owner | Gift(G) | 300K | — | $0 |
| May 28, 2026 | Burnam Bradley Evan | Chief Executive Officer, Director, 10% Owner | Gift(G) | 300K | — | $0 |
| Apr 2, 2026 | Burnam Bradley Evan | Chief Executive Officer, Director, 10% Owner | Gift(G) | 300K | — | $0 |
| Apr 2, 2026 | Golden Arthur F | Director | Gift(G) | 300K | — | $0 |
| Apr 1, 2026 | Chaudhary Zuraiz | See Remarks | Grant(A) | 80K | — | $0 |
| Apr 1, 2026 | Burnam Bradley Evan | Chief Executive Officer, Director, 10% Owner | Grant(A) | 160K | — | $0 |
| Jan 7, 2026 | Dewhurst Martin William | Director | Grant(A) | 22K | — | $0 |
| Dec 12, 2025 | Chaudhary Zuraiz | See Remarks | Buy(P) | 3K | $3.50 | $9K |
| Nov 24, 2025 | Golden Arthur F | Director | Buy(P) | 10K | $3.44 | $34K |
| Nov 21, 2025 | Chaudhary Zuraiz | See Remarks | Buy(P) | 1K | $3.29 | $3K |
| Nov 21, 2025 | Golden Arthur F | Director | Buy(P) | 21K | $2.87 | $59K |
| Nov 20, 2025 | Chaudhary Zuraiz | See Remarks | Buy(P) | 1K | $2.61 | $4K |
| Nov 17, 2025 | Chaudhary Zuraiz | See Remarks | Buy(P) | 3K | $3.62 | $9K |
| Oct 23, 2025 | Golden Arthur F | Director | Buy(P) | 20K | $4.95 | $100K |
| Oct 23, 2025 | Chaudhary Zuraiz | See Remarks | Buy(P) | 5K | $4.95 | $25K |
| Oct 23, 2025 | Chesed Abraham | Insider | Buy(P) | 14K | $4.60 | $66K |
| Oct 8, 2025 | Gengos Andrew | Director | Grant(A) | 10K | — | $0 |
| Oct 8, 2025 | Golden Arthur F | Director | Grant(A) | 10K | — | $0 |
| Oct 8, 2025 | Chaudhary Zuraiz | See Remarks | Grant(A) | 240K | — | $0 |
| Oct 8, 2025 | Kester Kent Edward | Director | Grant(A) | 10K | — | $0 |
| Oct 8, 2025 | Ghodadra Neilesh Shailesh | Chief Medical Officer, Director | Grant(A) | 10K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Turn Therapeutics Inc., SEC CIK 0002023016. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under TTRX and shows every filing by that issuer. Earlier filings under the same symbol by another issuer are left out.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-05. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for TTRX